Although the clinical implications of these interactions have been poorly studied, alterations in DNAM-1 expression lead to higher relapse rates in AML [42] and higher susceptibility to solid and hematologic cancers [43,44,45,46]. The gene discussed is CD226; the disease is acute myeloid leukemia.